Agendia, Genomic Health Present New MammaPrint, Oncotype DX Data at Breast Cancer Symposium

Although Agendia and Genomic Health's multi-gene assays differ in terms of their indications for highly specific breast cancer populations, the two companies are competitors in the overall breast cancer molecular diagnostics space, and are racing to expand their platforms into other cancer types.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.